Article

Bisphosphonate label revised to include dental exam recommendation

Novartis and the FDA have revised the prescribing information of zoledronic acid (Zometa) to include the occurrence of osteonecrosis of the jaw.

Novartis and the FDA have revised the prescribing information of zoledronic acid (Zometa) to include the occurrence of osteonecrosis of the jaw. The updated information recommends that cancer patients receive a dental examination prior to initiating therapy with IV bisphosphonates and avoid invasive dental procedures while receiving bisphosphonate treatment.

For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition, the FDA said.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Yahir A. Santiago-Lastra, MD, answers a question during a Zoom video interview
Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Anna Myers, CNP, answers a question during a Zoom video interview
Drug costs | Image Credit: © pixelrobot - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.